These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 38040479)

  • 21. MPrEP+ study protocol: a prospective cohort study assessing the feasibility and acceptability of an HIV pre-exposure prophylaxis (PrEP) strategy for male clients of female sex workers in Kisumu, Kenya.
    Mantell J; Franks J; Zerbe A; Lamb MR; Reed DM; Omollo D; Lahuerta M; Naitore D; El-Sadr WM; Agot K
    BMJ Open; 2022 Nov; 12(11):e064037. PubMed ID: 36332953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preexposure Prophylaxis for the Prevention of HIV Infection: Evidence Report and Systematic Review for the US Preventive Services Task Force.
    Chou R; Evans C; Hoverman A; Sun C; Dana T; Bougatsos C; Grusing S; Korthuis PT
    JAMA; 2019 Jun; 321(22):2214-2230. PubMed ID: 31184746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prospective study of oral pre-exposure prophylaxis initiation and adherence among young women in KwaZulu-Natal, South Africa.
    Mansoor LE; Lewis L; Naicker CL; Harkoo I; Dawood H; Naidoo K; Gengiah TN; Samsunder N; Beesham I; Abdool Karim SS; Abdool Karim Q
    J Int AIDS Soc; 2022 Jul; 25(7):e25957. PubMed ID: 35785472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
    Molina JM; Charreau I; Spire B; Cotte L; Chas J; Capitant C; Tremblay C; Rojas-Castro D; Cua E; Pasquet A; Bernaud C; Pintado C; Delaugerre C; Sagaon-Teyssier L; Mestre SL; Chidiac C; Pialoux G; Ponscarme D; Fonsart J; Thompson D; Wainberg MA; Doré V; Meyer L;
    Lancet HIV; 2017 Sep; 4(9):e402-e410. PubMed ID: 28747274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial.
    Deutsch MB; Glidden DV; Sevelius J; Keatley J; McMahan V; Guanira J; Kallas EG; Chariyalertsak S; Grant RM;
    Lancet HIV; 2015 Dec; 2(12):e512-9. PubMed ID: 26614965
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incentives conditioned on tenofovir levels to support PrEP adherence among young South African women: a randomized trial.
    Celum CL; Gill K; Morton JF; Stein G; Myers L; Thomas KK; McConnell M; van der Straten A; Baeten JM; Duyver M; Mendel E; Naidoo K; Dallimore J; Wiesner L; Bekker LG
    J Int AIDS Soc; 2020 Nov; 23(11):e25636. PubMed ID: 33247553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential Impact and Cost-Effectiveness of Condomless-Sex-Concentrated PrEP in KwaZulu-Natal Accounting for Drug Resistance.
    Phillips AN; Cambiano V; Johnson L; Nakagawa F; Homan R; Meyer-Rath G; Rehle T; Tanser F; Moyo S; Shahmanesh M; Castor D; Russell E; Jamieson L; Bansi-Matharu L; Shroufi A; Barnabas RV; Parikh UM; Mellors JW; Revill P
    J Infect Dis; 2021 Apr; 223(8):1345-1355. PubMed ID: 31851759
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Low Disclosure of PrEP Nonadherence and HIV-Risk Behaviors Associated With Poor HIV PrEP Adherence in the HPTN 067/ADAPT Study.
    Ojeda VD; Amico KR; Hughes JP; Wilson E; Li M; Holtz TH; Chitwarakorn A; Grant RM; Dye BJ; Bekker LG; Mannheimer S; Marzinke M; Hendrix CW
    J Acquir Immune Defic Syndr; 2019 Sep; 82(1):34-40. PubMed ID: 31169769
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protocol for a longitudinal study to evaluate the use of tenofovir-based PrEP for safer conception and pregnancy among women in South Africa.
    Matthews LT; Jaggernath M; Kriel Y; Smith PM; O'Neil K; Haberer JE; Hendrix C; Baeten JM; Ware NC; Wirth K; Psaros C; Bangsberg DR; Smit JA
    BMJ Open; 2019 Jul; 9(7):e027227. PubMed ID: 31350241
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychosocial determinants of pre-exposure prophylaxis use among pregnant adolescent girls and young women in Cape Town, South Africa: A qualitative study.
    Haribhai S; Khadka N; Mvududu R; Mashele N; Bekker LG; Gorbach P; Coates TJ; Myer L; Joseph Davey DL
    Int J STD AIDS; 2023 Jul; 34(8):548-556. PubMed ID: 36947792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. On-demand pre-exposure prophylaxis with tenofovir disoproxil fumarate plus emtricitabine among men who have sex with men with less frequent sexual intercourse: a post-hoc analysis of the ANRS IPERGAY trial.
    Antoni G; Tremblay C; Delaugerre C; Charreau I; Cua E; Rojas Castro D; Raffi F; Chas J; Huleux T; Spire B; Capitant C; Cotte L; Meyer L; Molina JM;
    Lancet HIV; 2020 Feb; 7(2):e113-e120. PubMed ID: 31784343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "These Girls Have a Chance to be the Future Generation of HIV Negative": Experiences of Implementing a PrEP Programme for Adolescent Girls and Young Women in South Africa.
    Duby Z; Bunce B; Fowler C; Jonas K; Bergh K; Govindasamy D; Wagner C; Mathews C
    AIDS Behav; 2023 Jan; 27(1):134-149. PubMed ID: 35793053
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data.
    Schaefer R; Amparo da Costa Leite PH; Silva R; Abdool Karim Q; Akolo C; Cáceres CF; Dourado I; Green K; Hettema A; Hoornenborg E; Jana S; Kerschberger B; Mahler H; Matse S; McManus H; Molina JM; Reza-Paul S; Azwa I; Shahmanesh M; Taylor D; Vega-Ramirez H; Veloso VG; Baggaley R; Dalal S
    Lancet HIV; 2022 Apr; 9(4):e242-e253. PubMed ID: 35271825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study.
    Molina JM; Ghosn J; Assoumou L; Delaugerre C; Algarte-Genin M; Pialoux G; Katlama C; Slama L; Liegeon G; Beniguel L; Ohayon M; Mouhim H; Goldwirt L; Spire B; Loze B; Surgers L; Pavie J; Lourenco J; Ben-Mechlia M; Le Mestre S; Rojas-Castro D; Costagliola D;
    Lancet HIV; 2022 Aug; 9(8):e554-e562. PubMed ID: 35772417
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of Trends in Rates of Sexually Transmitted Infections Before vs After Initiation of HIV Preexposure Prophylaxis Among Men Who Have Sex With Men.
    McManus H; Grulich AE; Amin J; Selvey C; Vickers T; Bavinton B; Zablotska I; Vaccher S; Jin F; Holden J; Price K; Yeung B; Cabrera Quichua G; Ogilvie E; McNulty A; Smith D; Guy R
    JAMA Netw Open; 2020 Dec; 3(12):e2030806. PubMed ID: 33355675
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-retroviral Therapy Based HIV Prevention Among a Sample of Men Who Have Sex with Men in Cape Town, South Africa: Use of Post-exposure Prophylaxis and Knowledge on Pre-exposure Prophylaxis.
    Hugo JM; Stall RD; Rebe K; Egan JE; De Swardt G; Struthers H; McIntyre JA
    AIDS Behav; 2016 Dec; 20(Suppl 3):357-364. PubMed ID: 27631366
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Whatever is in the ARVs, is Also in the PrEP" Challenges Associated With Oral Pre-exposure Prophylaxis Use Among Female Sex Workers in South Africa.
    Makhakhe NF; Sliep Y; Meyer-Weitz A
    Front Public Health; 2022; 10():691729. PubMed ID: 35784260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alignment of PrEP adherence with periods of HIV risk among adolescent girls and young women in South Africa and Zimbabwe: a secondary analysis of the HPTN 082 randomised controlled trial.
    Velloza J; Donnell D; Hosek S; Anderson PL; Chirenje ZM; Mgodi N; Bekker LG; Marzinke MA; Delany-Moretlwe S; Celum C
    Lancet HIV; 2022 Oct; 9(10):e680-e689. PubMed ID: 36087612
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Retention, engagement, and adherence to pre-exposure prophylaxis for men who have sex with men and transgender women in PrEP Brasil: 48 week results of a demonstration study.
    Grinsztejn B; Hoagland B; Moreira RI; Kallas EG; Madruga JV; Goulart S; Leite IC; Freitas L; Martins LMS; Torres TS; Vasconcelos R; De Boni RB; Anderson PL; Liu A; Luz PM; Veloso VG;
    Lancet HIV; 2018 Mar; 5(3):e136-e145. PubMed ID: 29467098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protocol for an open-label, single-arm trial of HIV pre-exposure prophylaxis (PrEP) among people at high risk of HIV infection: the NSW Demonstration Project PRELUDE.
    Vaccher S; Grulich A; McAllister J; Templeton DJ; Bloch M; McNulty A; Holden J; Poynten IM; Prestage G; Zablotska I;
    BMJ Open; 2016 Jun; 6(6):e012179. PubMed ID: 27324719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.